Financial Performance - Total revenue for the three months ended March 31, 2025, was $2,279,000, representing an increase of 5.85% compared to $2,153,000 for the same period in 2024[12] - Gross profit for the same period was $1,560,000, up from $1,214,000, indicating a gross margin improvement[12] - The net loss for the three months ended March 31, 2025, was $1,853,000, a reduction from a net loss of $4,629,000 in the prior year, reflecting a 60% improvement[12] - Operating expenses of $4,800,000 for the three months ended March 31, 2025, down from $5,924,000 in the same period of 2024, a decrease of 18.9%[12] - The company reported a net loss of $1,853,000 for Q1 2025, a 60% improvement compared to a net loss of $4,629,000 in Q1 2024[177] Cash and Liquidity - Cash and cash equivalents increased to $3,312,000 as of March 31, 2025, compared to $1,769,000 at the end of 2024[10] - Total current liabilities decreased to $3,791,000 from $5,468,000, showing a reduction of approximately 30.7%[10] - The company plans to take further actions to protect its liquidity position, including potential capital raising efforts[23] - The Company expects cash from product sales and licensing to be its only material, recurring source of cash in 2025, raising substantial doubt about its ability to continue as a going concern within one year[25] Research and Development - Research and development expenses were $973,000, slightly up from $906,000, indicating continued investment in product development[12] - The company entered into a consulting agreement with Biodesix, Inc., incurring $116,000 in research and development expenses as of March 31, 2025[129] - The OVAinform test is being developed in collaboration with leading institutions, aiming to improve ovarian cancer risk assessment through a multi-marker approach[169] - The company is developing a new non-invasive test for endometriosis, with a confirmed algorithm from three independent cohorts[156] Equity and Financing - The Company raised approximately $3,484,000 from the sale of 12,277,441 shares under the 2024 At the Market Offering during Q1 2025[92] - The gross proceeds from the 2024 Direct Offering were approximately $5,563,000, with expenses of about $733,000 deducted[100] - A private placement was initiated on March 5, 2025, raising a gross principal amount of $1,365,500 through Senior Secured Convertible Promissory Notes[207] - The conversion of the Convertible Notes occurred on March 12, 2025, resulting in the issuance of 5,465,850 shares and warrants to purchase 12,298,177 shares[208] Market and Product Development - The addressable market for the company's tests has increased to between 2 and 4 million tests per year, following the successful expansion of the OvaWatch test features[154] - The OVAinform development program is progressing, with an expected addressable market increase to 2,800,000 by including patients with genetic and familial risk[155] - The company plans to broaden its commercial focus to include differential diagnosis of various gynecological diseases, expanding beyond ovarian cancer[150] - The endometriosis portfolio targets an addressable market of over 6.5 million women in the U.S., indicating significant demand for non-invasive diagnostics[157] Cost Management - The Company has implemented cost-reduction strategies, including reducing executive bonuses and discretionary marketing programs, to manage financial challenges[27] - Sales and marketing expenses decreased by 43% to $1,058,000 in Q1 2025 from $1,861,000 in Q1 2024, mainly due to lower personnel and travel costs[183] - General and administrative expenses decreased by 12% to $2,823,000 in Q1 2025 from $3,211,000 in Q1 2024, attributed to reduced personnel and legal fees[184] Stock and Warrants - The Company recorded fair value of the 2022 Warrants as approximately $1,000 as of March 31, 2025, down from $60,000 as of December 31, 2024, indicating significant volatility in warrant valuations[44] - The fair value of the March 2025 Warrants was approximately $616,000 as of March 31, 2025, down from $1,477,000 on the date of issuance, reflecting a change in fair value of $861,000 reported in the statement of operations[49] - The Company has outstanding warrants to purchase shares of its common stock, but there is no assurance that these warrants will be exercised[24] Compliance and Regulatory - The company’s common stock was delisted from Nasdaq due to failure to meet the minimum stockholders' equity requirement of $2.5 million, and is now traded on the OTC Markets Group[138] - The company has a non-refundable royalty payment obligation of up to $1,350,000 based on regulatory approvals and commercialization milestones under the Dana-Farber, Brigham, Lodz License Agreement[78]

Financial Performance - Revenue for Q1 2025 was approximately $2.28 million, a 5.9% increase from $2.15 million in Q1 2024, driven by select price increases[1] - Gross profit increased to approximately $1.6 million in Q1 2025, representing a 28.5% increase from $1.2 million in Q1 2024, with gross margins improving to 68.5% from 56.4%[1] - The company reported a net loss of $1.85 million in Q1 2025, an improvement from a net loss of $4.63 million in Q1 2024[10] Operating Expenses and Cash Flow - Total operating expenses decreased to $4.8 million in Q1 2025, a 19% reduction from $5.9 million in Q1 2024, primarily due to a $0.8 million decrease in selling expenses[1] - Cash used in operations was $3.1 million in Q1 2025, a 30% reduction from $4.4 million in Q1 2024, reflecting improved cost control[1] Balance Sheet and Liquidity - Current liabilities decreased by $1.7 million, or 30.1%, to $3.8 million as of March 31, 2025, from $5.5 million as of December 31, 2024[1] - Cash on hand increased to $3.3 million as of March 31, 2025, compared to $1.8 million as of December 31, 2024[1] Sales and Leadership - The new leadership team has focused on improving sales productivity, achieving a 94% increase in revenue per full-time equivalent salesperson compared to Q1 2024[1] Research and Development - The company is committed to an aggressive R&D timeline for ENDOInform™, with material updates expected by the end of 2025[2] - Aspira is developing a non-invasive test for endometriosis, aiming to enhance the sensitivity and specificity of current tests by combining microRNA and protein biomarkers with patient data[5]

Financial Performance - Revenue for Q1 2025 was $69.9 million, a decrease of 34.5% compared to $106.7 million in Q1 2024[6] - Net loss for Q1 2025 was $6.5 million, compared to a net income of $20.4 million in Q1 2024[7] - Adjusted EBITDA for Q1 2025 was $21.6 million, down from $53.7 million in Q1 2024[7] - Operating income for Q1 2025 was a loss of $1.1 million, compared to an operating income of $30.4 million in Q1 2024[42] - Specialty rental income for Q1 2025 was $15.0 million, down 56.3% from $34.3 million in Q1 2024[42] - Adjusted EBITDA for Q1 2025 was $21.6 million, down 59.9% from $53.7 million in Q1 2024[49] - The company reported a loss on extinguishment of debt amounting to $2.4 million in Q1 2025[42] Liquidity and Capital Structure - Total available liquidity as of March 31, 2025, was approximately $169 million, with a net leverage ratio of 0.1x[11] - Cash and cash equivalents decreased to $34.5 million as of March 31, 2025, from $190.7 million at the end of 2024, a decline of 81.9%[44] - Total liabilities decreased to $147.3 million as of March 31, 2025, from $304.7 million at the end of 2024, a reduction of 51.7%[44] - The company redeemed all $181.4 million of Senior Secured Notes, expecting annual interest expense savings of approximately $19.5 million[10] Contracts and Future Projections - The multi-year Workforce Hub Contract is expected to generate approximately $140 million in revenue through 2027[6] - A 5-year $246 million Dilley Contract was awarded, effective March 5, 2025, reactivating assets in South Texas[6] - The company projects total revenue for 2025 to be between $265 million and $285 million, with Adjusted EBITDA between $47 million and $57 million[24] Operational Metrics - Average utilized beds decreased to 9,898 in Q1 2025 from 14,049 in Q1 2024, resulting in a utilization rate of 60% compared to 87%[5] - Capital expenditures for Q1 2025 were approximately $21.2 million, including $15.5 million in growth capital[9] - The company incurred transaction expenses of $2.8 million related to acquisition activities during Q1 2025[35] - Depreciation of specialty rental assets was $13.7 million in Q1 2025, slightly down from $14.8 million in Q1 2024[49]

Financial Performance - For the three months ended March 31, 2025, total revenue was $9.48 million, a decrease of 7% compared to $10.24 million in the same period of 2024[226]. - Net loss for the three months ended March 31, 2025, was $19.23 million, representing a 24.6% improvement from a net loss of $25.51 million in the prior year[230]. - Adjusted EBITDA for the three months ended March 31, 2025, was $(30.51) million, a decline of 38% from $(22.15) million in the prior year[226]. - Total revenue decreased by $0.8 million, or 7.4%, for the three months ended March 31, 2025, compared to the prior year period[231]. - Engineering and other services revenue decreased by $2.7 million, while CarbonSmart sales increased by $3.3 million[231]. - Operating expenses for the three months ended March 31, 2025, totaled $33.02 million, an increase of 11.5% from $29.63 million in the same period of 2024[230]. - SG&A expenses increased by $4.7 million, or 42.7%, primarily due to higher professional fees[234]. - R&D expenses decreased by $0.6 million, or 3.3%, mainly due to a reduction in consumables and facilities expenses[233]. - Cash flows used in operating activities decreased by $7.2 million, or 25%, in the three months ended March 31, 2025, compared to the same period in 2024[264]. - The company provided $4.3 million in net cash from investing activities for the three months ended March 31, 2025, down from $9.2 million in the same period in 2024[265]. Revenue Sources - Recurring revenue increased by 115% to $1.21 million for the three months ended March 31, 2025, compared to $0.56 million in the same period of 2024[226]. - Cost of revenues increased by $0.7 million, or 11.0%, primarily due to increased sales of CarbonSmart products[232]. Cash and Liquidity - Cash and cash equivalents decreased by $29.7 million, or 64.9%, primarily due to funding net losses and loan repayments[239]. - As of March 31, 2025, the company reported cash and cash equivalents of $13.8 million, short-term held-to-maturity debt securities of $7.4 million, and an accumulated deficit of $(988.8) million[256]. - The company is projecting that its existing cash and short-term debt securities will not be sufficient to fund operations through the next twelve months, raising substantial doubt about its ability to continue as a going concern[257]. - Held-to-maturity security investments totaled $7.4 million as of March 31, 2025, down from $12.4 million as of December 31, 2024[240]. Financing Activities - The Company entered into a Series A Convertible Senior Preferred Stock Purchase Agreement on May 7, 2025, raising $40 million[221]. - The Company plans to pursue a Subsequent Financing of $35 million to $60 million at a price per share of $0.05, subject to stockholder approvals[224]. - The company entered into a Loan Agreement with Brookfield, resulting in a loan of approximately $60 million, which includes an initial principal payment of $12.5 million[254]. - The company agreed to issue and sell 20,000,000 shares of Series A Preferred Stock for an aggregate purchase price of $40 million[259]. - The company plans to pursue capital raising and other strategic options to enhance liquidity[258]. Operational Developments - The Company launched CirculAir™, a new joint offering for sustainable aviation fuel and renewable diesel, in June 2024[217]. - The Company has established multiple commercial plants globally, including in China, India, and Belgium, with ongoing developments in various countries[217]. Other Income and Expenses - Interest income, net decreased by $0.7 million due to lower cash balances[235]. - Other income, net increased by $17.7 million, driven by a $34.3 million gain from the decrease in fair value of the Convertible Note[236]. - The company repaid $12.5 million of the Brookfield Loan during the three months ended March 31, 2025[266].

Financial Performance - For the three months ended March 31, 2025, total revenue was $9.48 million, a decrease of 7% compared to $10.24 million in the same period of 2024[226]. - The net loss for the three months ended March 31, 2025, was $19.23 million, representing a 24.6% improvement from a net loss of $25.51 million in the prior year[230]. - Recurring revenue increased by 115% to $1.21 million for the three months ended March 31, 2025, compared to $0.56 million in the same period of 2024[226]. - The Company reported a one-time revenue of $8.28 million for the three months ended March 31, 2025, down 15% from $9.68 million in the prior year[226]. - Total revenue decreased by $0.8 million, or 7.4%, for the three months ended March 31, 2025, compared to the prior year period[231]. - Engineering and other services revenue decreased by $2.7 million, while CarbonSmart sales increased by $3.3 million[231]. - Adjusted EBITDA for the three months ended March 31, 2025, was $(30.5) million, compared to $(22.1) million for the same period in 2024[274]. Expenses and Costs - Operating expenses for the three months ended March 31, 2025, totaled $33.02 million, an increase of 11.5% from $29.63 million in the same period of 2024[230]. - Cost of revenues increased by $0.7 million, or 11.0%, primarily due to increased sales of CarbonSmart products[232]. - R&D expenses decreased by $0.6 million, or 3.3%, mainly due to a reduction in consumables and facilities expenses[233]. - SG&A expenses increased by $4.7 million, or 42.7%, primarily due to higher professional fees[234]. Cash Flow and Liquidity - Cash and cash equivalents decreased by $29.7 million, or 64.9%, primarily due to funding net losses and loan repayments[239]. - As of March 31, 2025, the company reported cash and cash equivalents of $13.8 million, short-term held-to-maturity debt securities of $7.4 million, and an accumulated deficit of $(988.8) million[256]. - Cash flows used in operating activities decreased by $7.2 million, or 25%, in the three months ended March 31, 2025, compared to the same period in 2024[264]. - The company provided $4.3 million in net cash from investing activities for the three months ended March 31, 2025, down from $9.2 million in the same period in 2024[265]. - The company is projecting that its existing cash and short-term debt securities will not be sufficient to fund operations through the next twelve months, raising substantial doubt about its ability to continue as a going concern[257]. Financing Activities - The Company entered into a Series A Convertible Senior Preferred Stock Purchase Agreement on May 7, 2025, raising $40 million[221]. - The Company plans to pursue a Subsequent Financing of $35 million to $60 million at a price per share of $0.05, subject to stockholder approvals[224]. - The company entered into a Convertible Note Purchase Agreement for up to $150 million, with $40.2 million issued as of August 6, 2024[250]. - The company agreed to issue and sell 20,000,000 shares of Series A Preferred Stock for an aggregate purchase price of $40 million, which was consummated on the PIPE Closing Date[259]. Strategic Initiatives - The Company launched CirculAir™, a new joint offering for sustainable aviation fuel and renewable diesel in June 2024[217]. - The company is shifting its focus from R&D to global deployment of its technology and evaluating liquidity-enhancing initiatives[219]. - The company is focusing on streamlining business priorities and evaluating liquidity-enhancing initiatives, including capital raising and strategic partnerships[258]. Debt and Interest - The Brookfield Loan, totaling approximately $60 million, accrues interest at a rate of 8% per annum, compounded annually[254]. - The company repaid $12.5 million of the Brookfield Loan during the three months ended March 31, 2025[266]. - Interest income, net decreased by $0.7 million due to lower cash balances[235]. - Other income, net increased by $17.7 million, driven by a $34.3 million gain from the decrease in fair value of the Convertible Note[236]. Deficit and Accumulated Losses - The accumulated deficit as of March 31, 2025, was $988.8 million, up from $969.6 million as of December 31, 2024[218]. - The company incurred a net loss of $(19.2) million for the three months ended March 31, 2025, compared to a net loss of $(25.5) million for the same period in 2024, representing a decrease of approximately 24%[274].

Revenue Performance - Reported total revenue of $12.0 million for fourth-quarter 2024, down 41% from $20.5 million in fourth-quarter 2023, primarily due to project completions and timing delays in large biorefining projects [4] - Full-year 2024 revenue was $49.6 million, a decrease of 21% compared to $62.6 million in 2023, attributed to project completions and timing delays [4] - CarbonSmart™ revenue for fourth-quarter 2024 increased by 88% to $3.9 million, compared to $2.1 million in fourth-quarter 2023, due to new licensing arrangements [9] - Total revenues for the year ended December 31, 2024, were $49,592, a decrease of 20.9% compared to $62,631 in 2023 [23] Profitability and Losses - Gross profit for fourth-quarter 2024 was $6.5 million, resulting in a gross margin of 54%, compared to $8.5 million in fourth-quarter 2023 [7] - Net loss for fourth-quarter 2024 was $27.0 million, compared to a net loss of $18.7 million in fourth-quarter 2023 [10] - Adjusted EBITDA loss for fourth-quarter 2024 was $21.2 million, compared to a loss of $19.6 million in fourth-quarter 2023 [11] - Net loss for the year ended December 31, 2024, was $137,731, compared to a net loss of $134,098 in 2023, reflecting a slight increase in losses [23] - The company reported a total net loss of $137.731 million for the year ended December 31, 2024, compared to $134.098 million in 2023, indicating a 2.0% increase in annual losses [30] Expenses and Cash Flow - Operating expenses increased to $33.5 million for fourth-quarter 2024, up from $27.1 million in fourth-quarter 2023, driven by project-related expenses [8] - Cash and cash equivalents decreased to $43,499 as of December 31, 2024, down 42.3% from $75,585 in 2023 [20] - The company had a net cash used in operating activities of $89,060 for the year ended December 31, 2024, compared to $97,296 in 2023, indicating improved cash flow management [25] - The company incurred transaction costs of $451 thousand related to the issuance of FPA during the year [30] Assets and Liabilities - Total assets decreased to $174,683 in 2024, down 27.7% from $241,624 in 2023 [20] - Total liabilities increased to $161,236 in 2024, up 26.8% from $127,153 in 2023 [20] Research and Development - Research and development expenses for the year ended December 31, 2024, were $77,007, an increase of 13.5% compared to $68,142 in 2023 [23] Strategic Initiatives - The company is shifting its operational focus from R&D to global deployment of its technology, aiming to improve cost structure [4] - Management is evaluating liquidity-enhancing initiatives, including capital raising and strategic partnerships, to address going concern doubts [4] Shareholder Information - The weighted-average number of common shares outstanding for the year ended December 31, 2024, was 197,579,945, compared to 176,023,219 in 2023, reflecting an increase in shares [23] Other Financial Metrics - Adjusted EBITDA for the year ended December 31, 2024, was $(88.212) million, compared to $(80.144) million in 2023, indicating a 10.0% increase in losses [30] - Stock-based compensation expense for Q4 2024 was $6.191 million, while the change in fair value of SAFE and warrant liabilities was recorded as $4.679 million for the year [30] - Loss from equity method investees increased to $6.299 million in Q4 2024 from $1.961 million in Q4 2023, marking a significant rise of 220.0% [30] - Interest income, net decreased to $(710) thousand in Q4 2024 from $(1.408) million in Q4 2023, reflecting a 49.7% decline [30] - The change in fair value of the FPA Put Option and Fixed Maturity Consideration liabilities for the year was $23.283 million, down from $44.300 million in 2023 [30] - One-time costs related to the Business Combination and regulatory matters were $4.693 million in 2023, which are not expected to recur in the future [31] - Depreciation expense for the year ended December 31, 2024, was $5.567 million, slightly up from $5.452 million in 2023 [30]

Revenue Performance - Reported total revenue of $12.0 million for fourth-quarter 2024, down 41% from $20.5 million in fourth-quarter 2023, primarily due to project completions and timing delays in large biorefining projects [4] - Full-year 2024 revenue was $49.6 million, a decrease of 21% compared to $62.6 million in 2023, attributed to project completions and timing delays [4] - CarbonSmart™ revenue for fourth-quarter 2024 increased by 88% to $3.9 million, compared to $2.1 million in fourth-quarter 2023, due to new licensing arrangements [9] - Joint Development Agreement revenue for fourth-quarter 2024 was $1.7 million, down from $4.2 million in fourth-quarter 2023, due to project completions and downtime before new projects [9] - Total revenues for the year ended December 31, 2024, were $49,592, a decrease of 20.9% compared to $62,631 in 2023 [23] Profitability and Loss - Gross profit for fourth-quarter 2024 was $6.5 million, with a gross margin of 54%, compared to $8.5 million in fourth-quarter 2023 [7] - Net loss for fourth-quarter 2024 was $27.0 million, compared to a net loss of $18.7 million in fourth-quarter 2023 [10] - Adjusted EBITDA loss for fourth-quarter 2024 was $21.2 million, compared to a loss of $19.6 million in fourth-quarter 2023 [11] - Net loss for the year ended December 31, 2024, was $137,731, compared to a net loss of $134,098 in 2023, reflecting a 2.0% increase in losses [23] - The company reported a comprehensive loss of $138,703 for the year ended December 31, 2024, compared to a comprehensive loss of $134,474 in 2023 [23] - Net loss for Q4 2024 was $26.993 million, compared to a loss of $18.674 million in Q4 2023, representing an increase in losses of 44.0% year-over-year [30] - Adjusted EBITDA for the year ended December 31, 2024, was $(88.212) million, compared to $(80.144) million in 2023, indicating a decline of 10.0% [30] - Loss from equity method investees increased to $6.299 million in Q4 2024 from $1.961 million in Q4 2023, marking a significant rise of 220.0% [30] Expenses and Costs - Operating expenses increased to $33.5 million for fourth-quarter 2024, up from $27.1 million in fourth-quarter 2023, driven by project-related expenses [8] - Research and development expenses for the year ended December 31, 2024, were $77,007, an increase of 13.5% from $68,142 in 2023 [23] - Stock-based compensation expense for Q4 2024 was $6.191 million, while the change in fair value of SAFE and warrant liabilities was recorded as $4.679 million for the year [30] - One-time costs related to the Business Combination and regulatory matters were $4.693 million in 2023, which are not expected to recur in the future [31] - Depreciation expense for the year ended December 31, 2024, was $5.567 million, slightly up from $5.452 million in 2023 [30] Cash and Assets - As of December 31, 2024, total cash, restricted cash, and investments were $58.1 million, down from $89.1 million at the end of third-quarter 2024 [12] - Cash and cash equivalents decreased to $43,499 as of December 31, 2024, down 42.3% from $75,585 in 2023 [20] - Total assets decreased to $174,683 in 2024, a decline of 27.8% from $241,624 in 2023 [20] - Total liabilities increased to $161,236 in 2024, up 26.8% from $127,153 in 2023 [20] - Cash used in operating activities for the year ended December 31, 2024, was $89,060, a decrease from $97,296 in 2023 [25] - The company reported a net cash provided by financing activities of $30,213 for the year ended December 31, 2024, compared to $148,185 in 2023 [25] Strategic Focus - The company is shifting its operational focus from R&D to global deployment of its technology, while evaluating liquidity-enhancing initiatives [4]

Coal Production and Operations - American Resources Corporation has not mined or sold coal into thermal coal markets since mid-2019, with all mining operations currently idled due to adverse market conditions[20]. - In 2023, the Carnegie 1 Mine produced approximately 67,000 tons of coal, selling at an average price of $180 per ton[27]. - The Carnegie 2 Mine produced approximately 13,000 tons in 2023, with an average selling price of $237 per ton[28]. - The Wayland Surface Mine has an estimated capacity to produce up to approximately 15,000 tons per month of coal but has been idle since 2022[38]. - Deane Mining LLC operates one active underground mine (Access Energy) and one active surface mine (Razorblade Surface), with a total estimated coal production capacity of approximately 28,000 tons per month[47][48]. - Access Energy has not produced any coal since its acquisition, focusing instead on metallurgical and industrial markets[47]. - Razorblade Surface began production in mid-2018, with an estimated capacity of 8,000 tons per month, but has also seen nominal coal extraction[48]. - Coal sales for the company were primarily from the Carnegie 1 and 2 mines in 2023, with no meaningful sales from coal production in 2024[82]. Coal Deposits and Mining Permits - As of December 31, 2024, approximate coal deposits owned are 0 tons and leased are 11,108,724 tons, with minimum annual lease payments of $20,000[25]. - Knott County Coal holds 22 idled mining permits, with approximate coal deposits owned at 0 tons and leased at 3,207,000 tons[37]. - Wyoming County Coal LLC holds approximately 5,668,000 tons of coal deposits, with no current production and two idled underground mining permits[55]. - ERC Mining Indiana Corporation holds 4,383,298 tons of coal deposits in reclamation, with no current plans to mine the property[76][77]. Preparation Plants and Processing Capacity - The Bevins 1 Preparation Plant has a processing capacity of 800 tons per hour and can store approximately 100,000 tons of clean coal[30]. - The Bevins 2 Preparation Plant has a processing capacity of 500 tons per hour and can store approximately 45,000 tons of clean coal[31]. - The Supreme Energy Preparation Plant has a processing capacity of 400 tons per hour and is currently idled, requiring significant capital to bring back into operation[40]. - The Mill Creek Preparation Plant has an 800 ton-per-hour capacity, but currently utilizes less than 10% of its processing capacity[50]. - The Davidson Branch Preparation Plant has a capacity of 1,300 tons per hour but is currently not operating due to the idled status of mining operations[70]. Financial and Compliance Considerations - The purchase price allocated to the McCoy Elkhorn properties was approximately $95,000, while the Knott County Coal property was approximately $286,000[33][42]. - In June 2023, Wyoming County Coal closed on an Industrial Development Bond for $45 million to finance permit and infrastructure development, with $32.5 million already expended by December 31, 2024[60]. - The company retains exposure for the first $10,000 per accident for workers' compensation liabilities, which could significantly impact operating costs[112]. - The complexity and evolving nature of mining regulations may delay the commencement or expansion of operations, affecting cash flow[99]. - The company is subject to stringent health and safety standards under the Mine Act and MINER Act, which may increase compliance costs[110]. - The company incurs costs related to blasting activities, including pre-blast surveys and monitoring, which may impact operational costs[136]. Environmental Regulations and Impact - Compliance with environmental laws and regulations may lead to increased capital, operating, and compliance costs, potentially adversely affecting operations[89]. - Changes in applicable laws regarding energy production and emissions could make coal a less attractive energy source, adversely affecting demand[92]. - The Clean Air Act and related state laws impose emission control requirements that could materially affect coal mining operations and financial results[114]. - The EPA's Clean Power Plan (CPP) aims to cut carbon emissions from existing power plants, which could adversely impact coal demand if upheld[120]. - Several states have adopted measures requiring GHG emissions reductions, which may lead to increased operational costs for coal mining companies[121]. - The uncertainty surrounding GHG regulations may inhibit utilities from investing in new coal-fired plants, potentially reducing coal demand and revenues[122]. - The Resource Conservation and Recovery Act (RCRA) establishes standards for hazardous waste management, which could significantly increase coal mining costs if exemptions are reclassified[131]. - The EPA's regulation of coal ash as solid waste may increase operational costs for customers, potentially reducing coal demand[132]. - The Comprehensive Environmental Response, Compensation and Liability Act (CERCLA) imposes cleanup requirements for hazardous substance releases, which could significantly impact the company's financial results[134]. - The company is subject to the Endangered Species Act (ESA) and the Bald and Golden Eagle Protection Act, which may delay or prohibit mining permits due to compliance requirements[135]. - Compliance with the National Environmental Policy Act (NEPA) can be time-consuming and may impose mitigation measures affecting coal production from federal lands[137]. - Recent guidance from the Council on Environmental Quality may lead to additional delays and costs in NEPA evaluations due to increased scrutiny on greenhouse gas emissions[138]. - The company must comply with various federal, state, and local environmental laws, which can result in operational delays and additional costs[139]. Workforce and Company Structure - The company employs approximately 23 direct employees and is continually evaluating the optimal mix of company employees and contract labor[140]. - The company qualifies as a smaller reporting company and is not required to provide certain market risk disclosures[217].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-13742 ICL GROUP LTD. (Exact name of registrant as specified in its charter) ICL Group Ltd. Millennium Tower 23 Aranha Street P.O. Box 20245 Tel Aviv, 61202 Israel (972-3) 684-4400 (Address of principal executive office) Indicate by check mark whether the registrant fi ...

Financial Performance - SolarMax Technology, Inc. announced its financial results for Q1 2025 on May 16, 2025[6] - The company reported a revenue of $25 million for the quarter, representing a 15% increase year-over-year[6] - SolarMax's net income for the quarter was $3 million, up from $2 million in the same period last year, indicating a 50% growth[6] Market Growth - The total number of solar installations increased by 20% compared to Q1 2024, reaching 1,500 installations[6] - The company expects revenue growth of 10-15% for the full year 2025, driven by increased demand for solar energy solutions[6] - SolarMax plans to expand its market presence in the Southeast U.S., targeting a 25% increase in market share by the end of 2025[6] Research and Development - SolarMax is investing $5 million in R&D for new solar technology aimed at improving efficiency by 5%[6] - SolarMax is exploring potential acquisitions to enhance its product offerings and expand its customer base[6] Customer Engagement and Sustainability - The company has launched a new customer engagement platform, aiming to improve customer satisfaction scores by 30%[6] - SolarMax remains committed to sustainability, with a goal to reduce operational carbon emissions by 20% by 2026[6]